Protecting the World from Pertussis and Other Emerging Diseases
BioNet is a leading developer and manufacturer of vaccines, specializing in recombinant and mRNA-based solutions targeting respiratory diseases and other global public health challenges. With a proven track record in research, development, and biomanufacturing, BioNet has successfully advanced proprietary recombinant pertussis vaccines from early-stage innovation to licensure.
BioNet Achieves EU-GMP Certification for its Pertussis Vaccine Manufacturing
Lyon, France – October 29, 2025, BioNet today announced it has received European Union Good Manufacturing Practice (EU-GMP) certification, an internationally recognized benchmark of pharmaceutical quality and compliance, to produce its acellular pertussis vaccine.“This milestone underscores BioNet’s resolute dedication to world-class manufacturing standards and marks a key step in the ongoing centralized regulatory review of its recombinant acellular pertussis vaccine candidate, VacPertagen, by the European Medicines Agency (EMA).” said Philippe Guillot-Chêne, CEO, BioNet in Europe.
The EU-GMP certification confirms that BioNet’s facilities, quality systems and quality controls meet the highest international criteria.
“The certificate was received following the inspection of BioNet production site by the Ireland Health Products Regulatory Authority (HPRA).” added Dario Cresci, Director Quality. “This achievement reflects BioNet’s long-standing culture of excellence and commitment to provide public health authorities with innovative solutions to the global pertussis resurgence.”